Leishmaniasis

Postgraduate Medical Journal

Volumn 82, Issue 972, 2006, Pages 649-657

  Piscopo, T V ^a   Mallia, A C ^a  

^a ST LUKE S HOSPITAL   (Malta)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; FLUCONAZOLE; GAMMA INTERFERON; IMIQUIMOD; KETOCONAZOLE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; SITAMAQUINE; STEROID; STIBOGLUCONATE SODIUM;

AMERICAN LEISHMANIASIS; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DISEASE CONTROL; DISEASE COURSE; DISEASE TRANSMISSION; ENDEMIC DISEASE; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGY; INCIDENCE; LEISHMANIA; LEISHMANIASIS; NEPHROTOXICITY; OTOTOXICITY; PREVALENCE; REVIEW; SEASONAL VARIATION; SKIN LEISHMANIASIS; SYMPTOM; VISCERAL LEISHMANIASIS;

HIV INFECTIONS; HUMANS; LEISHMANIASIS; OPPORTUNISTIC INFECTIONS;

EID: 33751231734     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2006.047340     Document Type: Review

References (97)

1. Desjeux P. Leishmaniosis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004;27:305-18.
2. Murray HW. Kala-azar-progress against a neglected disease. N Engl J Med 2002;22:347, 1793-1794.
3. Guerin PJ, Olliaro P, Sundar S, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infet Dis 2002;2:494-501.
4. Herwaldt BL. Leishmaniasis. Lancet 1999;354:1191-99.
5. Arias JR, Monteiro PS, Zicker F. The re-emergence of visceral leishmaniosis in Brazil. Emerg Infect Dis 1996;2:145-146.
6. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001;95:239-43.
7. Kuhn KG. Global warming and Leishmaniasis in Italy. Bull Trop Med Int Health 1999;7:1-2.
8. Hsia R. Leishmaniasis. 2005. http://wwwemedicine.com 2005. http://www.emedicine.com/emerg/topic296.htm (accessed 28 Aug 2006).
9. Lainson R, Shaw JJ. Evolution, classification and geographic distribution. In: Peters W, Killick-Kendrick R, eds. The leishmaniases in biology and medicine. V.1 London: Academic Press, 1987:1-120.
10. Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th edn. Elsevier, 2005:2428-2442.
11. Zijlstra EE, El-Hassan AM. Visceral leishmaniasis. Tram Roy Soc Trop Med Hyg 2001;95(Suppl 1):S27-58.
12. Murray HW, Berman JD, Davies CR et al. Advances in leishmaniasis. Lancet 2005;366:1561-77.
13. Grech V, Mizzi J, Mangion M, et al. Visceral leishmaniasis in Malta - an 18 year paediatric, population based study. Arch Dis Child 2000;82:381-5.
14. Gradoni L, Gramiccia M, Léger N et al. Isoenzyme characterization of Leishmania from man, dog and sandflies in the Maltese islands. Trans Roy Soc Trop Med Hyg 1991;85:217-9.
15. De Alencar JE, Neves J, Leishmaniose visceral (calazar). In: Veronesi R, ed. In: Doencas infecciosas e parasitarias, 7th edn. Rio de Janeiro: Editora Guanabara Koogan SA, 1982:724.
16. Manson-Bahr PEC, Southgate BA, Harvey AEC. Development of kala-azar in man after inoculation with a leishmania from a Kenyo sandfly. BMJ 1963;1:1208-10.
17. Manson-Bahr PEC, Apted FIC. Leishmaniasis. In: Manson-Bahr PEC, Apted FIC, eds. Manson's tropical diseases. 18th edn. London: Bailliere Tindall, 1982:93-115.
18. Stone HH, Tool CD, Pugsley WS. Kala-azar (visceral leishmanisis): report of a case with 34 month incubation period and positive Doan-Wright test. Ann Intern Med 1952;36:686-93.
19. Wilson ME, Streit JA. Visceral leishmaniasis. Gastroenterol Clin North Am 1996;25:535-51.
20. Zijlstra E E, El-Hassan AM. Post kala-azar dermal leishmaniasis. Trans Roy Soc Trop Med Hyg 2001;95(Suppl 1):S59-76.
21. Smith PAJ. Long incubation period in Leishmaniasis. BMJ 1955;2:1143.
22. Marsden PD, Nonata RR. Mucocutaneous leishmanisis - a review of clinical aspects. Rev Soc Bras Med Trop 1975;9:309-26.
23. Stark CG, Wortmann G. Leishmaniasis. http://www.emedicine.com 2006http://www.emedicine.com/MED/topic1275.htm (accessed 28 Aug 2006).
24. Heinzel FP, Sadick MD, Holaday BJ, et al. Reciprocal expression of Interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989;169:59-72.
25. Reiner SL, Wang ZE, Hatam F et al. TH1 and TH2 cell antigen receptors in experimental leishmaniasis. Science 1993;259:1457-60.
26. Reed SG, Scott P. T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol 1993;5:524-31.
27. Sundar S, Reed SG, Sharma S, et al. Circulating T helper 1(TH1) cell- and TH2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg 1997;56:522-5.
28. Roberts LJ, Handman E, Foote SJ. Leishmaniasis. BMJ 2000;321:801-4.
29. Costa CHN, Stewart JM, Gomes RBB, et al. Asymptomatic human carriers of Leishmania chagasi. Am J Trop Med Hyg 2002;66:334-7.
30. Dereure J, Duong Thanhb H, et al. Visceral leishmaniasis. Persistence of parasites in lymph nodes after clinical cure. J Inf 2003;47:77-81.
31. Sundar S, Sahu M, Mehta H, et al. Noninvasive management of Indian visceral leshmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. Clin Infect Dis 2002;35:581-6.
32. Salotra P, Sreenivas G, Pogue GP, et al. Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala- azar dermal leishmaniasis. J Clin Microbiol 2001;39:849-54.
33. Sundar S, Agrawal S, Pai K, et al. Detection of leishmanial antigen in the urine of patients with visceral leishmaniasis by latex agglutination test. Am J Trop Med Hyg 2005;73:268-71.
34. Islam MZ, Itoh M, Mirza R, et al. Direct agglutination test with urine samples for the diagnosis of visceral leishmaniasis. Am J Trop Med Hyg 2004;70:78-82.
35. Belli A. Simplified polymerase chain reaction detection of new world Leishmania in clinical specimens of cutaneous leishmaniasis. Am J Trop Med Hyg 1998;58:102-109.
36. de Oliveira CI, Bafica A, Oliveira F, et al. Clinical utility of polymerase chain reaction-based detection of Leishmania in the diagnosis of American cutaneous leishmaniasis. Clin Infect Dis 2003;37:e149-153.
37. Camargo ME, Rebonato C. Cross-reactivity in immuno-fluorescence test for Trypanosoma and Leishmania antibodies. A simple inhibition procedure to ensure specific results. Am J Trop Med Hyg 1969;18:500-5.
38. Lugo de yarbuh A. Studies of the leishmanin skin test positivity in cases with treatment anti-leishmania. Parasitol Dia 1997;21:76-80.
39. de Lima Barros MB, Schubach A, Francesconi-do-Valle AC, et al. Positive Montenegro skin test among patients with sporotrichosis in Rio De Janeiro. Acte Trop 2005;93:41-7.
40. Sundar S, Jha TK, Thakur CP, et al. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003;37:800-4.
41. Wortmann G, Miller RS, Oster C, et al. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Inf Dis 2002;35:261-7.
42. Report of a World Health Organisation Expert Committee. Control of the leishmaniasis. Geneva: WHO Technical Report Series 293, 1990.
43. Gallin JI, Farber JM, Holland SM, et al. Interferon-gamma in the management of infectious diseases. Ann Int Med 1995;123:216-24.
44. Gradoni I, Gramiccia M, Scalone A. Visceral leishmaniasis treatment, Italy. Emerg Infect Dis [serial online] 2003 Dec. http://www.cdc.gov/ncidod/EID/ vol9no12/03-0178.htm.
45. Syriopoulou V, Daikos GL, Theodoridou M, et al. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 2003;36:560-6.
46. Sundar S, Agrawal G, Rai M, et al. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001;323:419-22.
47. Sundar S, Makharia A, More DK, et al. Short-course of oral Miltefosine for treatment of visceral leishmaniasis. Clin Inf Dis 2000;31:1110-13.
48. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. New Engl J Med 1999;341:1795-1800.
49. Sundar S, Jha TK, Thakur CP et al. Oral Miltefosine for Indian visceral leishmaniasis. New Engl J Med 2002;347:1739-46.
50. Sinha PK, Ranjan A, Singh VP et al. Visceral leishmaniasis (kala-azar) - the Bihar (India) perspective. J Infect, 2005. doi: 10, 1016/i.jinf.2005.09.011.
51. Jha TK. Evaluation of diamidine compound (pentamidine isethionate) in the treatment resistant cases of kala-azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg 1983;77:167-70.
52. Jha TK. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 1998;316:1200-5.
53. Rosenthal E, Marty P. Recent understanding in the treatment of visceral leishmaniasis. J Postgrad Med 2003;49:61-8.
54. Sherwood JA, Gachihi GS, Muiggai RK, et al. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 1994;19:1034-9.
55. Dietze R, Carvalho SF, Valli LC, et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 2001;65:685-9.
56. Slum J, Desjeux, Schwartz E, et al. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 2004;53:158-166.
57. Bassiouny A, El Meshad M, Talaat M, et al. Cryosurgery in cutaneous leishmaniasis. Br J Dermatol 1982;107:467-74.
58. Gurei MS, Tatli N, Ozbilge H, et al. Efficacy of cryotherapy and intralesional pentostam in treatment or cutaneous leishmaniasis. J Egypt Soc Parasitol 2000;30:169-76.
59. Junaid AJ. Treatment of cutaneous leishmaniasis with infrared heat. Int J Dermatol 1986;25:470-2.
60. Garnier T, Croft L. Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs 2002;3:538-44.
61. Bryceson AD, Murphy A, Moody AH. Treatment of 'Old World' cutaneous leishmaniasis with aminosidine ointment: results of an open study in London. Trans R Soc Trop Med Hyg 1994;88:226-8.
62. Arevalo I, Ward B, Miller R, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of Imiquimod, an immunomodulator. Clin Infect Dis 2001;33:1847-51.
63. Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin infect Dis 1993;16:417-25.
64. Soto J, Buffet P, Grogl M, et al. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg 1994;50:107-11.
65. Alrajhi AA, Ibrahim EA, De Vol EB, et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002;346:891-5.
66. Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med 1990;89:147-55.
67. Soto J, Arana BA, Toledo J, et al. Miltefosine for New world cutaneous leishmaniasis. Clin Infect Dis 2004;38:1266-72.
68. Brown M, Noursadeghi M, Boyle J, et al. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol 2005;153:203-5.
69. Devlin RK, Parsonnet J, Klaus SN. Treatment of relapsed cutaneous Leishmania (Viannia) braziliensis Infection with liposomal Amphotericin B. Infect Dis Clin Pract 2005;13:84-6.
70. Hepburn NC, Tidman MJ, Hunter JAA. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans Roy Soc Trop Med Hyg 1994;88:700-3.
71. Martinez S, Marr JJ. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 1992;326:741-4.
72. Franke ED, Wignall FS, Cruz ME, et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 1990;113:934-40.
73. Sampaio SAP, Castro RM, Dillon NL, et al. Treatment of mucocutaneous (American) leishmaniasis with amphotericin B: a report of 70 cases. Int J Dermatol 1971;10:179-181.
74. Amato VS, Nicodemo AC, Amato JG, et al. Mucocutaneous leishmaniasis associated with HIV infection treated successfully with liposomal amphotericin B (AmBisome). J Antimicrob Chemother 2000;46:341-2.
75. Paredes R, Munoz J, Diaz I, et al. Leishmaniasis in HIV infection. J Postgrad Med 2003;49:39-49.
76. World Health Organization The leishmaniasis and Leishmania/HIV coinfections. WHO tactsheet no 116, May, 2000.
77. Alvar J, Canavata C, Gutierreez-Solar B, et al. Leishmania and human immunodeficiency virus co-infection: the first 10 years. Clin Microbiol Rev 1997;10:298-319.
78. Cruz I, Morales MA, Noguer I, et al. Leishmania in discarded syringes from intravenous drug users, Lancet 2002;359:1124-5.
79. Pasquau F, Ena J, Sanchez R, et al. Leishmania HIV Mediterreanean Cooperative Group. Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region, Eur J Clin Microbiol Infect Dis 2005;24:411-8.
80. Laguna F, López-Vélez R, Pulido F, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. AIDS 1999;13:1063-70.
81. Goldsmith DR, Perry CM. Amphotericin B lipid complex: in visceral leishmaniasis. Drugs. 2004;64:1905-11;discussion 1912-3).
82. Sindermann H, Engel KR, Fischer C, et al. The Miltefosine Compassionate Use Program. Oral Miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection, Clin Infect Dis 2004;39:1520-3.
83. Lopez-Velez R, Videla S, Marquez M, et al. Spanish HIV-Leishmania Study Group. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004;53:540-3.
84. Berenguer J, Cosin J, Miralles P, et al. Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS 2000;14:2946-8.
85. Russo R, Nigro L, Panarello G, et al. Clinical survey of Leishmania/HIV coinfection in Catania, Italy: the impact of highly active antiretroviral therapy (HAART). Ann Trop Med Parasitol 2003;97(Suppl 1):149-55.
86. Reybum H, Ashford R, Mohsen M, et al. A randomized controlled trial of insecticide-treated bednets and chaddars or top sheets, and residual spraying of interior rooms for the prevention of cutaneous leishmaniasis in Kabul, Afghanistan. Trans R Soc Trop Med Hyg 2000;94:361-6.
87. Davies CR, Llanos-Cuentas EA, Campos P, et al. Spraying houses in the Peruvian Andes with lambda-cyhalothrin protects residents against cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 2000;94:631-6.
88. Bern C, Joshi AB, Jha SN, et al. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg 2000;63:184-8.
89. Davies CR, Kaye P, Croft SL, et al. Leishmaniasis: new approaches to disease control. BMJ 2003;326:377-82.
90. Carlos HN, Costa JM, Stewart RBB, et al. Asymptomatic Human Carriers Of Leishmania Chagasi. Am J Trop Med Hyg 2002;66:334-7.
91. del Giudice P, Mary-Krause M, Pradier C, et al. Impact of Highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with HIV. J Infect Dis 2002;186:1366-70.
92. Berberian DA. Vaccination and immunity against oriental sore. Trans Roy Soc Trop Med Hyg 1939;33:87-8.
93. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 2001;14:229-43.
94. Belkaid Y, Von Stebut E, Mendez S, et al. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 2002;168:3992-4000.
95. Rhee EG, Mendez S, Shah JA, et al. Vaccination with heat-killed Leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J Exp Med 2002;195:1565-73.
96. Khalil EAG, El Hassan AM, Zijlstra EE, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan, Lancet 2000;356:1565-9.
97. Gradoni L. An update on antileishmanial vaccine candidates and prospects fora canine Leishmania vaccine. Vet Parasitol 2001;100:87-103.